Epizyme (EPZM) Tops Q4 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
Go back to Epizyme (EPZM) Tops Q4 EPS by 12c
March 9, 2016 6:31 AM EST
Company reiterates financial runway guidance through at least the end
of 2017 and through major research and development milestones
Conference call to be held today at 8:00am E.T.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company
creating novel epigenetic therapies for patients with cancer, today
highlighted certain 2015 and recent accomplishments and reported
financial results for the fourth quarter of and full year 2015. In
addition, earlier today, Epizyme announced a multi-year vision for the
companys growth through 2020.
Key 2015... More
March 9, 2016 6:30 AM EST
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Epizyme, Inc., (NASDAQ: EPZM) a clinical stage biopharmaceutical company
creating novel epigenetic therapies for patients with cancer, today
announced its corporate vision and strategy through 2020. During the
next five years, Epizyme will focus on four transformative activities:
Transitioning to a commercial-stage organization through the global
launch of tazemetostat in patients with non-Hodgkin lymphoma (NHL) and
in patients with certain genetically defined solid tumors;
Expanding the clinical program for tazemetostat to support its
utilization in earlier lines of therapy, in...
More
